Charles Schwab Investment Management Inc. Has $1.58 Million Stock Holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Charles Schwab Investment Management Inc. lowered its stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 11.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,147,370 shares of the company’s stock after selling 150,272 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Lyell Immunopharma were worth $1,583,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in LYEL. Intech Investment Management LLC acquired a new stake in Lyell Immunopharma in the 3rd quarter worth $52,000. GSA Capital Partners LLP raised its position in Lyell Immunopharma by 1,285.5% in the 3rd quarter. GSA Capital Partners LLP now owns 354,815 shares of the company’s stock worth $490,000 after purchasing an additional 329,205 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Lyell Immunopharma by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 49,238 shares of the company’s stock valued at $68,000 after purchasing an additional 19,287 shares during the last quarter. Exchange Traded Concepts LLC raised its position in shares of Lyell Immunopharma by 37.3% during the 3rd quarter. Exchange Traded Concepts LLC now owns 135,050 shares of the company’s stock valued at $186,000 after acquiring an additional 36,715 shares during the last quarter. Finally, SG Americas Securities LLC lifted its stake in Lyell Immunopharma by 78.1% in the third quarter. SG Americas Securities LLC now owns 57,566 shares of the company’s stock valued at $79,000 after buying an additional 25,247 shares during the period. Institutional investors own 66.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on LYEL shares. Bank of America downgraded Lyell Immunopharma from a “buy” rating to an “underperform” rating and dropped their price objective for the stock from $6.00 to $1.00 in a research note on Wednesday, October 30th. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 target price on shares of Lyell Immunopharma in a research note on Tuesday, November 12th.

Lyell Immunopharma Stock Performance

NASDAQ:LYEL opened at $0.67 on Tuesday. The stock has a 50-day simple moving average of $1.04 and a 200 day simple moving average of $1.42. The company has a market cap of $195.87 million, a PE ratio of -0.85 and a beta of -0.45. Lyell Immunopharma, Inc. has a 52-week low of $0.65 and a 52-week high of $3.26.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.03. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. The firm had revenue of $0.03 million for the quarter. On average, research analysts predict that Lyell Immunopharma, Inc. will post -0.8 earnings per share for the current fiscal year.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.